TABLE 11. Off-label meningococcal vaccination recommendations for persons at increased risk for meningococcal disease, by age group and indication — Advisory Committee on Immunization Practices, United States, 2020.

Age group	Indication
≥2 yrs	Administration of a 2-dose MenACWY primary series in persons at increased risk for serogroups A, C, W, or Y meningococcal disease Repeated booster doses of MenACWY for certain persons who remain at increased risk for serogroups A, C, W, or Y meningococcal disease (MenACWY-D and MenACWY-CRM are licensed for a single booster dose for persons aged 15–55 yrs if at least 4 yrs have elapsed since the last dose. MenACWY-TT is licensed for a single booster dose for persons aged ≥15 yrs if at least 4 yrs have elapsed since the last dose of MenACWY)
≥10 yrs	MenB booster doses in certain persons who remain at increased risk for serogroup B meningococcal disease
≥26 yrs	MenB primary series administration in persons at increased risk for serogroup B meningococcal disease
≥56 yrs	Administration of MenACWY-D or MenACWY-CRM in persons at increased risk for serogroups A, C, W, or Y meningococcal disease

Abbreviations: MenACWY = quadrivalent meningococcal conjugate vaccine; MenACWY-CRM = meningococcal groups A, C, W, and Y oligosaccharide diphtheria CRM₁₉₇ conjugate vaccine; MenACWY-D = meningococcal groups A, C, W, and Y polysaccharide diphtheria toxoid conjugate vaccine; MenACWY-TT = meningococcal groups A, C, W, and Y polysaccharide tetanus toxoid conjugate vaccine; MenB = serogroup B meningococcal vaccine.